Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

4.1K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
4.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NAT10-Mediated ac4C Modification of circANKRD12 Reprograms the Tumor Microenvironment.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

PNPO-Mediated Oxidation of DVL3 Promotes Multiple Myeloma Malignancy and Osteoclastogenesis by Activating the Wnt/β-Catenin Pathway.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2024
Same author

Elevated SFXN2 limits mitochondrial autophagy and increases iron-mediated energy production to promote multiple myeloma cell proliferation.

Cell death & disease·2022
Same author

YTHDF2 promotes multiple myeloma cell proliferation via STAT5A/MAP2K2/p-ERK axis.

Oncogene·2022
Same author

BUB1B and circBUB1B_544aa aggravate multiple myeloma malignancy through evoking chromosomal instability.

Signal transduction and targeted therapy·2021
Same author

Suppression of steroid 5α-reductase type I promotes cellular apoptosis and autophagy via PI3K/Akt/mTOR pathway in multiple myeloma.

Cell death & disease·2021

Related Experiment Video

Updated: Apr 1, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K

Repurposing Hetrombopag for Multiple Myeloma by Targeting PNPO: A Celastrol-Inspired Approach.

Tianyi Yu1,2, Cheng Wang2, Jingru Xie2

  • 1Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.

Basic & Clinical Pharmacology & Toxicology
|March 31, 2026
PubMed
Summary

Pyridoxine-5'-phosphate oxidase (PNPO) drives multiple myeloma (MM) progression by promoting cell growth and osteoclast differentiation. The identified inhibitor, Hetrombopag, shows promise in clinical trials for MM treatment.

Keywords:
hetrombopagmultiple myelomaoxidationpyridoxine‐5′‐phosphate oxidasereactive oxygen species

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.6K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

911

Related Experiment Videos

Last Updated: Apr 1, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.6K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

911

Area of Science:

  • Oncology
  • Biochemistry
  • Pharmacology

Background:

  • Multiple myeloma (MM) pathogenesis involves reactive oxygen species (ROS) and elevated pyridoxine-5 '-phosphate oxidase (PNPO) expression.
  • PNPO, crucial for vitamin B6 metabolism, is implicated in cancer progression, including MM.
  • Celastrol, a Traditional Chinese Medicine compound, targets PNPO to induce cancer cell apoptosis.

Purpose of the Study:

  • To investigate the role of PNPO in MM progression.
  • To identify novel PNPO inhibitors for MM therapy.
  • To evaluate the therapeutic potential of Hetrombopag in MM.

Main Methods:

  • Structure-based virtual screening targeting PNPO residues R95 and K117.
  • Assessing PNPO expression in MM patient samples.
  • Evaluating Hetrombopag's effects on MM cell proliferation and osteoclast differentiation in vitro.
  • Analyzing preliminary clinical trial data.

Main Results:

  • PNPO is highly expressed in MM and correlates with disease progression.
  • Increased PNPO promotes MM cell proliferation and osteoclast differentiation via exosomes.
  • Hetrombopag identified as a PNPO inhibitor, effectively suppressing MM cell proliferation and osteoclast differentiation.
  • Early clinical data suggest Hetrombopag may prolong survival in MM patients.

Conclusions:

  • PNPO plays a critical role in multiple myeloma progression.
  • Hetrombopag demonstrates significant therapeutic potential as a PNPO inhibitor for MM treatment.
  • Further clinical investigation of Hetrombopag for MM is warranted.